C'mon, C'mon, Do the Locomotion... Recommendations and Guidelines for Patients on GLP-1RAs

Forgot your password?

Select specialty

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

March 14, 2024

Feat. M. Koren

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

ASPC 2019 Congress on CVD Prevention

Robert Busch

Cardiometabolic Health Congress (CMHC)

Diana Isaacs

Houston Methodist

T. R. Mccarty

Michigan Medicine

Diana Isaacs

Scripps Health

Scripps Health

McMaster University Department of Medicine

S. Boushahri, D. Lazzam, K. MacEachern

Canadian Collaborative Research Network

A. Michael Lincoff

Login

Login

Join VuMedi

C'mon, C'mon, Do the Locomotion... Recommendations and Guidelines for Patients on GLP-1RAs

Initiating and Monitoring Patients on a Non-Statin Lipid-Lowering Th…

Expert Insights on Adding a Non-Statin Lipid-Lowering Therapy in a R…

Recommended

Primer on Diabetes Management

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Labs to Check on Semaglutide or Tirzepatide

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Could GLP-1's be a 'Game Changer' For Weight Loss? Can it be a Safer…

Weightloss in Menopause

Tirzepatide Updates

Endoscopic Weight Loss Therapies - A Paradigm Shift in the Treatment…

Incretin-based Therapies in the Management of Obesity and its Comorb…

The Differences Between the Products of GLP1's and GLP/GIPs

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

Tirzepatide for Type 2 Diabetes

GLP-1 Hysteria

New Research: Side Effect of GLP1

Obesity: A Serious Cardiovascular Risk Factor? A Review of GLP-1 Rec…

Semaglutide: Where Are We Now and Where Are We Going?

An Introduction to Tirzepatide for Weightloss

Is Obesity Management the Next Frontier?